Overview Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) Status: Recruiting Trial end date: 2026-02-01 Target enrollment: Participant gender: Summary A Phase 1/2 dose escalation study of BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia (AML). Phase: Phase 1/Phase 2 Details Lead Sponsor: K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.